Peptide Guide + Calculator
Tesamorelin Reconstitution Calculator & Guide
Growth Hormone-Releasing Hormone Analog
Tesamorelin is a growth hormone-releasing hormone analog used in FDA-approved EGRIFTA products for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It stimulates endogenous growth hormone release and increases IGF-1. This page explains its approved use, clinical evidence, safety considerations, sports status, and educational reconstitution math.
Evidence Snapshot
Tesamorelin research at a glance
Standardized regulatory and evidence context so research compounds, investigational drugs, and approved medications are not treated as if they have the same level of human evidence.
Primary mechanism
GHRH receptor agonist that stimulates endogenous growth hormone release and downstream IGF-1.
WADA context
Explicitly prohibited — S2Human intervention evidence
Randomized clinical trials and FDA-reviewed evidence support EGRIFTA products for a specific HIV-associated lipodystrophy indication.
Human biology evidence
Human studies consistently show stimulation of the growth hormone axis and increases in IGF-1.
Key takeaway
Unlike most GH-axis peptides sold online, tesamorelin has an FDA-approved product, a defined clinical indication, and regulatory-grade human evidence.
Evidence labels describe the research base and regulatory context; they are not treatment, dosing, or use recommendations. Review dates describe the last BACToBasics source check for this evidence summary. Anti-doping rules can change and should be verified with the applicable authority.
Tesamorelin Reconstitution Calculator
Enter the vial amount, liquid volume, and amount you want to calculate. BACToBasics will automatically calculate concentration, liquid volume, and U-100 syringe-unit equivalents.
Loading calculator...
Calculator values are educational math inputs only. They are not recommended preparation amounts, doses, or use protocols.
Tesamorelin Reconstitution Math
Reconstitution math starts with the amount contained in the vial and the liquid volume used in the calculation. Dividing the vial amount by the liquid volume gives the resulting concentration.
Example vial amount
2 mg
| Liquid Volume | Calculation | Concentration |
|---|---|---|
| 1 mL | 2 mg ÷ 1 mL | 2 mg/mL |
| 2 mL | 2 mg ÷ 2 mL | 1 mg/mL |
| 3 mL | 2 mg ÷ 3 mL | 0.6667 mg/mL |
This table demonstrates concentration math only. The liquid volumes shown are examples for comparison and are not preparation recommendations.
More Reconstitution Tools
Need to compare different liquid volumes or convert between mg, mcg, mL, and U-100 units? Use the dedicated BACToBasics calculator tools.
What is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, also called GHRH or growth hormone-releasing factor. It stimulates the pituitary to release endogenous growth hormone, which in turn increases downstream insulin-like growth factor-1 (IGF-1). Tesamorelin is the active ingredient in FDA-approved EGRIFTA products.
What is Tesamorelin FDA-approved for?
FDA-approved EGRIFTA formulations are indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. This is a specific medical indication involving excess visceral abdominal fat in people with HIV. Tesamorelin is not approved as a general-purpose fat-loss, bodybuilding, anti-aging, or weight-management medication.
Tesamorelin is not a general weight-loss drug
FDA prescribing information explicitly states that EGRIFTA is not indicated for weight-loss management and describes the treatment as weight neutral. The clinical effect is focused on reduction of visceral abdominal fat rather than broad loss of total body weight.
How does Tesamorelin work?
Tesamorelin activates GHRH receptors in the pituitary and stimulates growth hormone secretion. Increased endogenous growth hormone signaling raises circulating IGF-1 and affects body-composition pathways, including visceral adipose tissue. This mechanism differs from directly administering growth hormone and also differs from ghrelin-receptor agonists such as Ipamorelin.
What have Tesamorelin clinical trials shown?
Randomized controlled trials in adults with HIV-associated abdominal fat accumulation showed significant reductions in visceral adipose tissue compared with placebo. In a 12-month study of 404 participants, visceral adipose tissue decreased by about 10.9% during the initial six-month randomized phase versus about 0.6% with placebo. Participants who continued treatment maintained and extended the visceral-fat reduction, while much of the improvement was lost after treatment was stopped.
Tesamorelin and liver fat
Clinical research has also investigated Tesamorelin in people with HIV and fatty liver disease. A randomized 2019 trial found a greater reduction in hepatic fat fraction with Tesamorelin than placebo over 12 months. These liver findings are clinically interesting but should not be confused with the FDA-approved indication, which remains reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
Tesamorelin and IGF-1
Because Tesamorelin stimulates endogenous growth hormone production, IGF-1 commonly rises during treatment. FDA labeling specifically warns about elevated IGF-1 and notes that the effects of prolonged IGF-1 elevation are not fully established. This is one reason medically supervised use includes laboratory monitoring rather than treating Tesamorelin as a routine wellness peptide.
Tesamorelin and glucose regulation
Growth hormone signaling can affect glucose metabolism. FDA labeling warns that glucose intolerance or diabetes can develop during Tesamorelin treatment. Clinical-trial data used in the label showed a higher proportion of participants developing an HbA1c of at least 6.5% with EGRIFTA than with placebo, so glucose monitoring is part of approved medical use.
Common Tesamorelin adverse effects
Common adverse effects reported in FDA labeling include joint pain, muscle pain, pain in the extremities, peripheral edema, and injection-site reactions such as redness and itching. Fluid-retention effects can also include edema, arthralgia, and carpal tunnel syndrome. Hypersensitivity reactions have occurred in clinical trials.
Important Tesamorelin safety considerations
FDA-approved Tesamorelin labeling includes warnings involving active or recurrent malignancy, persistently elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity, injection-site reactions, and use during acute critical illness. Approved formulations are also contraindicated in pregnancy and in people with disruption of the hypothalamic-pituitary axis or active malignancy.
EGRIFTA SV vs EGRIFTA WR
EGRIFTA SV and EGRIFTA WR are both FDA-approved Tesamorelin products, but they are different formulations with different strengths, preparation instructions, storage requirements, and labeled administration instructions. FDA labeling states that the formulations are not substitutable. A generic reconstitution calculator should therefore not be treated as a replacement for product-specific prescribing information.
Tesamorelin vs CJC-1295
Tesamorelin and CJC-1295 both act through the GHRH pathway, but they are not interchangeable compounds. Tesamorelin has an FDA-approved medical product and a defined clinical indication in HIV-associated lipodystrophy, while CJC-1295 remains an investigational peptide without an FDA-approved therapeutic indication.
Tesamorelin vs Ipamorelin
Tesamorelin is a GHRH analog that stimulates the growth hormone axis through the GHRH receptor. Ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor. They stimulate growth hormone release through different receptor systems and have very different regulatory and clinical-evidence profiles.
Is Tesamorelin banned in competitive sports?
Yes. The World Anti-Doping Agency lists Tesamorelin among prohibited growth hormone-releasing factors under Section S2 of the 2026 Prohibited List. Athletes subject to WADA rules should not assume that a medically available peptide is permitted in competition.
Tesamorelin reconstitution math
Reconstitution calculations depend on the labeled amount in a vial and the liquid volume used. As a mathematical example, a 2mg vial combined with 2mL of liquid produces a concentration of 1mg per mL. BACToBasics uses examples like this only to demonstrate concentration, liquid-volume, and U-100 syringe-unit calculations. FDA-approved EGRIFTA formulations have product-specific preparation instructions that should not be replaced by a generic calculator.
Explore more about Tesamorelin
15 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Explore more about Tesamorelin
15 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Compare Tesamorelin
Direct comparison pages are selected from the indexable BACToBasics comparison catalog and update automatically as that catalog grows.
Semaglutide vs Tesamorelin
Compare Semaglutide, Tesamorelin using the same evidence dataset.
Open →
ComparisonTesamorelin vs AOD-9604
Compare Tesamorelin, AOD-9604 using the same evidence dataset.
Open →
ComparisonTesamorelin vs CJC-1295
Compare Tesamorelin, CJC-1295 using the same evidence dataset.
Open →
ComparisonTesamorelin vs Ipamorelin
Compare Tesamorelin, Ipamorelin using the same evidence dataset.
Open →
Research, updates & development
Jump from the guide into the public update timeline, compound-specific research records, and clinical-development tracker without searching again.
Tesamorelin research & development updates
Open the public timeline of sourced research records and material development changes tracked by BACToBasics.
Open →
ResearchTesamorelin research sources
Open 2 curated research records for Tesamorelin.
Open →
DevelopmentTesamorelin clinical development
Approved · Approved. FDA-approved clinical use after Phase 3 development.
Open →
Blend guides containing Tesamorelin
These pages are derived from blend component metadata, so a new blend automatically becomes discoverable from each linked component guide.
Related peptide guides
Related guides are ranked from shared comparison pages, shared blend pages, and peptide category rather than a hand-maintained link list.
Ipamorelin guide & calculator
Growth Hormone & Performance · Growth Hormone Secretagogue / Ghrelin Receptor Agonist
Open →
Peptide guideCJC-1295 guide & calculator
Growth Hormone & Performance · Long-Acting Growth Hormone-Releasing Hormone Analog
Open →
Peptide guideAOD-9604 guide & calculator
Metabolic & Weight Loss · Modified Human Growth Hormone Fragment
Open →
Peptide guideSemaglutide guide & calculator
Metabolic & Weight Loss · GLP-1 Receptor Agonist
Open →
Relevant glossary concepts
Definitions are matched against the guide's structured title, subtitle, description, and educational sections.
FDA-Approved
A status indicating that the FDA has approved a specific drug product for one or more labeled uses after reviewing the required evidence and manufacturing information.
Open →
GlossaryMilliliter (mL)
A metric unit of liquid volume equal to one-thousandth of a liter.
Open →
GlossaryConcentration
The amount of a substance contained in a given volume of liquid, such as mg/mL or mcg/mL.
Open →
Tesamorelin FAQ
Tap a question to expand only the answer you want to read.
Is Tesamorelin FDA-approved?
Yes. Tesamorelin is the active ingredient in FDA-approved EGRIFTA products used for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
Is Tesamorelin approved for weight loss?
No. FDA prescribing information states that EGRIFTA is not indicated for weight-loss management and describes the treatment as weight neutral.
Does Tesamorelin reduce visceral fat?
Yes, in its studied and approved population. Randomized clinical trials in adults with HIV-associated abdominal fat accumulation demonstrated significant reductions in visceral adipose tissue compared with placebo.
Does Tesamorelin increase IGF-1?
Yes. Tesamorelin stimulates endogenous growth hormone production and increases IGF-1. FDA labeling specifically recommends monitoring because the effects of prolonged IGF-1 elevation are not fully known.
Can Tesamorelin affect blood sugar?
Yes. FDA labeling warns that glucose intolerance or diabetes can develop during treatment, which is why glucose status is monitored in approved medical use.
What are common Tesamorelin side effects?
Commonly reported adverse effects include joint pain, muscle pain, pain in the extremities, peripheral edema, and injection-site reactions. Fluid retention and hypersensitivity reactions are also important safety considerations.
Is Tesamorelin the same as growth hormone?
No. Tesamorelin is a GHRH analog that stimulates the pituitary to release the body's own growth hormone. It is not recombinant human growth hormone itself.
How is Tesamorelin different from CJC-1295?
Both act through the GHRH pathway, but Tesamorelin has an FDA-approved medical product and a defined indication in HIV-associated lipodystrophy. CJC-1295 remains investigational and is not an FDA-approved treatment.
How is Tesamorelin different from Ipamorelin?
Tesamorelin activates the GHRH receptor pathway, while Ipamorelin acts as a ghrelin-receptor growth hormone secretagogue. They stimulate growth hormone release through different receptor systems.
Is Tesamorelin being studied for fatty liver?
Yes. Randomized research in people with HIV and fatty liver disease has shown reductions in liver fat, but this is separate from Tesamorelin's FDA-approved indication.
Are EGRIFTA SV and EGRIFTA WR interchangeable?
No. FDA labeling states that the formulations differ in strength, preparation, storage, and administration instructions and are not substitutable.
Is Tesamorelin banned by WADA?
Yes. Tesamorelin is listed by WADA as a prohibited growth hormone-releasing factor under the 2026 Prohibited List.
How do you calculate Tesamorelin reconstitution concentration?
For concentration math, divide the labeled amount in the vial by the liquid volume. For example, 2mg divided by 2mL equals 1mg per mL. This is mathematical conversion, not a preparation recommendation for an FDA-approved product.
Can the BACToBasics calculator handle Tesamorelin math?
Yes. The calculator can perform concentration and unit-conversion math from user-entered values. It does not replace product-specific EGRIFTA prescribing information or medical instructions.
Sources & References
6 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Sources & References
6 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Official labeling covering the HIV-associated lipodystrophy indication, weight-neutral limitation, warnings, adverse effects, IGF-1 monitoring, glucose effects, and formulation-specific instructions.
FDA approval letter for the EGRIFTA WR formulation, approved in March 2025 as a new formulation and product presentation of Tesamorelin.
Randomized placebo-controlled Phase 3 study evaluating visceral adipose tissue and metabolic outcomes over 12 months.
Randomized clinical trial evaluating visceral adipose tissue and liver fat in adults with HIV and abdominal fat accumulation. DOI: 10.1001/jama.2014.8334.
Randomized multicenter trial evaluating hepatic fat fraction and liver outcomes in people with HIV and fatty liver disease. DOI: 10.1016/S2352-3018(19)30338-8.
Tesamorelin is listed under prohibited growth hormone-releasing factors in Section S2.
BACToBasics provides educational information and math tools only. This content is not medical advice, dosing advice, injection instruction, or a recommendation to use any peptide or medication.